Incorporating microarray assessment of HER2 status in clinical practice supports individualised therapy in early-stage breast cancer

Abstract Accurate determination of human epidermal growth factor receptor-2 (HER2) status is essential for optimal selection of breast cancer patients for gene targeted therapy. The analytical performance of microarray analysis using TargetPrint for assessment of HER2 status was evaluated in 138 bre...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Breast (Edinburgh) 2015-04, Vol.24 (2), p.137-142
Hauptverfasser:	Grant, Kathleen A, Pienaar, Fredrieka M, Brundyn, Karen, Swart, Gillaume, Gericke, George S, Myburgh, Ettienne J, Wright, Colleen A, Apffelstaedt, Justus P, Kotze, Maritha J
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Algorithms Analytical validation Biomarkers, Tumor - metabolism Breast cancer Breast Neoplasms - metabolism Breast Neoplasms - pathology Breast Neoplasms - therapy Carcinoma, Ductal, Breast - metabolism Carcinoma, Ductal, Breast - pathology Carcinoma, Ductal, Breast - therapy Carcinoma, Lobular - metabolism Carcinoma, Lobular - pathology Carcinoma, Lobular - therapy Female Hematology, Oncology and Palliative Medicine HER2 status Humans Immunohistochemistry In Situ Hybridization MammaPrint prescreen algorithm Middle Aged Neoplasm Staging Precision Medicine Quality assurance Quality Assurance, Health Care Receptor, ErbB-2 - metabolism TargetPrint microarray Tissue Array Analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!